Research programme: peptides - Biolingus

Drug Profile

Research programme: peptides - Biolingus

Alternative Names: Project B2 (OPUS/SLIT) - Biolingus; Project B3 (OPUS) - Biolingus; Project B5 (SLIT) - Biolingus

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biolingus
  • Class Antihyperlipidaemics; Antineoplastics; Antirheumatics; Biobetters; Dendritic cell vaccines; Peptides
  • Mechanism of Action Immunostimulants; PCSK9 protein inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Hypercholesterolaemia; Rheumatoid arthritis

Most Recent Events

  • 19 Sep 2017 The peptides are available for licensing as of 19 Sep 2017.
  • 19 Sep 2017 Preclinical trials in Cancer in Switzerland (Sublingual) before September 2017 (Biolingus pipeline, September 2017)
  • 19 Sep 2017 Preclinical trials in Hypercholesterolaemia in Switzerland (Sublingual) before September 2017 (Biolingus pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top